Divide Conquer is a biotechnology company focused on the discovery and development of novel oncology therapeutics that target specific cancer pathways. By utilizing advanced drug discovery techniques, the company aims to improve treatment efficacy and reduce side effects for patients with various types of cancer.
Funding
$12.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments lack specificity, leading to significant side effects and reduced efficacy due to their impact on healthy cells alongside cancerous ones. The development of more targeted therapies is crucial for improving patient outcomes and quality of life.
Solution
Divide Conquer is a biotechnology company dedicated to discovering and developing novel oncology therapeutics that selectively target specific cancer pathways. The company leverages advanced drug discovery techniques, including high-throughput screening and computational modeling, to identify and optimize molecules that disrupt key mechanisms driving cancer growth and survival. By focusing on precision medicine, Divide Conquer aims to create treatments that are more effective and have fewer off-target effects compared to traditional chemotherapy or radiation. Their approach seeks to personalize cancer therapy by targeting vulnerabilities unique to individual tumors.
Target Audience
Divide Conquer's primary target audience includes pharmaceutical companies seeking to expand their oncology pipelines, as well as academic research institutions focused on cancer biology and drug discovery.
Features
- High-throughput screening platform for identifying novel drug candidates
- Computational modeling to predict drug-target interactions and optimize molecule design
- Focus on specific cancer pathways, such as cell cycle regulation, DNA repair, and immune evasion
- Development of small molecule inhibitors and biologics
- Preclinical testing in cell-based and animal models to evaluate efficacy and safety